No Data
No Data
Earnings Preview: Valneva to Report Financial Results Pre-market on May 07
Guggenheim Maintains Valneva(VALN.US) With Buy Rating, Cuts Target Price to $15
Valneva Shares Slump After France Suspends Chikungunya Vaccine for Elderly
Reported Saturday, Valneva Provides Update On IXCHIQ Chikungunya Vaccine Use Following HAS Recommendation And Safety Investigation
French Health Agency Suspends Use of Valneva's Chikungunya Jab for 65 Years Old and Above
Valneva Provides Update on ACIP Recommendation for Its Chikungunya Vaccine IXCHIQ Among U.S. Travelers